FLT3 and acute myeloid leukemia: In the venetoclax and A1331825 combination treated AML gene mutation status of TET2, FLT3, and TP53 as well as CD34, levels were inconsequential, IDH2 mutation and elevated blast cell percentage were associated with response, while the presence of PTPN11 or ASXL1 mutation indicated lack of response (Figure 7).